摘要
目的评价奥氮平治疗首发精神分裂症的疗效与安全性。方法对36例住院首发精神分裂症患者给予奥氮平治疗,起始剂量5mg·d-1,1w内根据病情调整至治疗剂量10～25mg·d-1,平均剂量16.33±5.24mg·d-1。疗程8w。分别于治疗前及治疗第2、4、8w末采用潘氏量表评定临床疗效,副反应量表评定不良反应。结果治疗2、4、8w末潘氏量表评分与治疗前比较差异有极显著性(P均<0.01)。其中痊愈15例(41.7%),显进12例(33.3%),进步6例(16.7%),无效3例(8.3%),总有效率91.7%。不良反应轻微,无明显心血管系统不良反应。结论奥氮平治疗首发精神分裂症安全有效,值得临床推广应用。
Objective To evaluate the efficacy and safety of olanzapine in the treatment of first-episode schizophrenia. Methods 36 hospitalized first-episode schizophrenics were treated with olanzapine, initial dosage was 5mg/d raised to 10~25mg/d within one week and mean dosage 16.33±5.24mg/d for 8 weeks. Efficacies and side effects were assessed with the Positive and Negative Symptoms Scale(PANSS) and Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of week 2,4 and 8 during treatment, respectively. Results The PANSS scores at the 3 time-points during treatment all were significant different from pre-treatment( all P<0.01).Of the 36 patients,15(41.7%) were recovery,12(33.3%) significant improvement,6(16.7%) improvement and 3(8.3) ineffective, the total effective rate was 91.7%. The side effects were milder, it had no obvious side effects of cardiovascular system. Conclusion Olanzapine is a safe and effective in the treatment of first-episode schizophrenia, and deserve to be clinically popularized.
出处
《临床心身疾病杂志》
CAS
2005年第3期228-229,共2页
Journal of Clinical Psychosomatic Diseases
关键词
奥氮平
首发精神分裂症
疗效
Olanzapine
first-episode schizophrenia
efficacy
